StockData
Roivant Sciences Ltd. logo

Roivant Sciences Ltd. (ROIV) shareholders

ROIVNasdaqPharmaceutical PreparationsFiscal year ends March 31
Số liệu tài chính tới Q1 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 9, 2026Score 7/30
$38.71+0.10 (+0.26%)

Close on Nov 17, 2026Market cap $27.96BP/E –Yield –

Ownership

Institutional holdings as of Jun 30, 2026, from 13F filings

Held by institutions
78.1%
564M of 722M shares
Institutional holders
498
100 new, 40 sold out
Net institutional buying
38M
In Q2 2026
Insider trades, 12 months
0 buys · 120 sales
Net sold $877.39M

Shares held by institutions

Holders of more than 5%

Latest Schedule 13D (active) or 13G (passive) filed by each holder

HolderShares% of classFilingAs of
Dan Oren102,849,443–13G (passive) amendmentDec 31, 2023
FMR LLC
Joint filing with Abigail P. Johnson (11.80%)
85,575,55211.80%13G (passive) amendmentSep 30, 2026
Abigail P. Johnson
Joint filing with FMR LLC (10.30%)
73,641,25310.30%13G (passive) amendmentFeb 27, 2026
BlackRock, Inc.59,285,1838.20%13G (passive) amendmentSep 30, 2026
Morgan Stanley
Joint filing with Morgan Stanley Investment Management Inc. (5.50%)
40,693,3865.70%13G (passive) amendmentJun 30, 2026
SVF Holdings (UK) LLP
Joint filing with SB Investment Advisers (UK) Limited (5.80%), SoftBank Vision Fund L.P. (5.80%) and 1 more
40,315,1275.80%13G (passive) amendmentSep 30, 2025
Viking Global Investors LP
Joint filing with Halvorsen Ole Andreas (5.02%), Ott David C. (5.02%) and 1 more
34,237,7795.02%13G (passive) amendmentJun 30, 2025

Top institutional holders

13F holdings as of Jun 30, 2026

HolderShares% of ROIVValueChange% of portfolio
FMR LLC81,020,39011.22%$2.87B+3,039,1370.12%
BlackRock, Inc.48,236,0916.68%$1.71B+3,981,8310.03%
Morgan Stanley42,592,9055.90%$1.51B−9,235,4200.08%
QVT Financial LP23,723,0743.28%$839.56M−1,438,16350.52%
Vanguard Capital Management LLC22,123,1983.06%$782.94M+1,442,6260.02%
Vanguard Portfolio Management LLC21,641,3393.00%$765.89M+1,802,6410.03%
Goldman Sachs Group Inc18,556,4582.57%$656.71M+7,444,8670.06%
State Street Corp17,795,9752.46%$629.80M+1,609,3620.02%
UBS Group AG17,466,6412.42%$618.14M−5,152,8310.08%
Assenagon Asset Management S.A.16,725,9042.32%$591.93M+9,649,4160.37%
Farallon Capital Management LLC14,309,0001.98%$506.40M+4,634,0002.34%
Geode Capital Management, LLC11,674,3801.62%$425.54M+1,491,9030.02%
Adage Capital Partners Gp, L.L.C.10,349,3281.43%$366.26M−2,444,7690.51%
Two Seas Capital LP8,475,3561.17%$299.94M−852,9355.94%
Perceptive Advisors LLC8,085,4611.12%$286.14M−200,0004.30%
Patient Square Capital LP8,020,9281.11%$283.86M−145,11943.97%
Invesco Ltd.7,531,1921.04%$266.53M+1,092,0470.02%
Darwin Global Management, Ltd.6,747,3000.93%$234.33M−50,0006.23%
Aqr Capital Management LLC6,633,5600.92%$234.03M+686,7020.08%
Viking Global Investors LP6,271,4670.87%$221.95M−380,9810.63%

Institutional buying and selling by quarter

Positions opened, added to, reduced and closed by 13F filers

QuarterHoldersShares held% of sharesNew / addedReduced / closedShares boughtShares sold
Q2 2026498564M78.1%100 / 202141 / 4083M45M
Q1 2026444531M73.5%97 / 174121 / 47125M62M
Q4 2025400509M70.5%110 / 15094 / 40106M98M
Q3 2025338503M69.6%59 / 12496 / 5650M63M
Q2 2025338516M71.5%61 / 115110 / 3553M95M
Q1 2025313558M77.2%57 / 91107 / 5927M29M
Q4 2024319563M77.9%69 / 93104 / 4131M40M
Q3 2024294572M79.2%54 / 12269 / 52109M47M
Q2 2024294547M75.7%64 / 10283 / 2655M111M
Q1 2024259604M83.6%69 / 9263 / 34139M99M
Q4 2023225564M78.1%61 / 8652 / 4184M65M
Q3 2023206546M75.6%53 / 8847 / 2788M40M

Top mutual fund and ETF holders

Latest monthly portfolio reports (Form N-PORT)

151 funds held ROIV in Q2 2026, 88% of their shares through ETFs. Each fund counts once per quarter, from its quarter-end report.

FundShares% of ROIVValue% of fundAs of
Vanguard Total Stock Market Index Fund15,987,7372.21%$565.81M0.02%Jun 30, 2026
Vanguard Small-Cap Index Fund11,546,2801.60%$408.62M0.22%Jun 30, 2026
Vanguard Small-Cap Growth Index Fund6,658,6160.92%$235.65M0.50%Jun 30, 2026
Invesco S&P MidCap Momentum ETF5,219,1920.72%$176.98M2.47%Jul 31, 2026
Vanguard Extended Market Index Fund5,168,6260.72%$182.92M0.19%Jun 30, 2026
Vanguard Explorer Fund2,969,4850.41%$100.70M0.46%Jul 31, 2026
Dimensional U.S. Core Equity 2 ETF1,165,4230.16%$39.52M0.08%Jul 31, 2026
Vanguard Health Care Index Fund1,128,2320.16%$33.84M0.18%May 31, 2026
iShares Russell 1000 Value ETF1,093,6520.15%$38.70M0.05%Jun 30, 2026
Vanguard S&p Mid-Cap 400 Index Fund719,4730.10%$21.58M0.39%May 31, 2026
Invesco BuyBack AchieversTM ETF582,8640.08%$19.76M0.87%Jul 31, 2026
College Retirement Equities Fund - Total Global Stock Account519,1870.07%$18.37M0.01%Jun 30, 2026
Bridge Builder Large Cap Growth Fund505,6690.07%$17.90M0.06%Jun 30, 2026
Vanguard Total World Stock Index Fund416,2930.06%$14.12M0.01%Jul 31, 2026
Nuveen Equity Index Fund380,9660.05%$12.92M0.02%Jul 31, 2026

Officers, directors and major owners

People who filed Forms 3, 4 or 5 in the last two years

NameRoleShares owned% of sharesLatest filing
Mayukh SukhatmePresident & CIO, Director20,054,4012.78%Nov 12, 2026
Matthew GlineCEO, Director16,391,2292.27%Nov 12, 2026
Richard PulikCFO222,0460.03%Nov 12, 2026
Eric VenkerPresident & Immunovant CEO811,2110.11%Nov 12, 2026
Frank TortiPresident and Vant Chair12,306,9501.70%Nov 12, 2026
Jennifer HumesChief Accounting Officer106,4190.01%Sep 22, 2026
Rakhi KumarChief Accounting Officer162,3060.02%Feb 24, 2025
James C. MomtazeeDirector112,2650.02%Oct 27, 2026
Epperly Melissa B,Director15,3510.00%Oct 27, 2026
Ilan OrenDirector124,4900.02%Oct 27, 2026
Daniel Allen GoldDirector22,654,9813.14%Sep 18, 2026
Keith S. ManchesterDirector15,442,6232.14%Sep 18, 2026
Meghan FitzgeraldDirector41,1620.01%Sep 18, 2026
Financial LP QVT–13,689,1661.90%Jun 30, 2026
Vivek Ramaswamy10% owner47,490,3206.57%Dec 15, 2025

Insider trades

Common stock transactions reported on Form 4, newest first

InsiderDateTransactionSharesPriceValueShares after
Frank Torti
President and Vant Chair
Nov 12, 2026Tax withholding−12,800$41.85$535.68K12,306,950
Frank Torti
President and Vant Chair
Nov 12, 2026Other−62,493$41.13$2.57M12,319,750
Frank Torti
President and Vant Chair
Nov 12, 2026Other−329,550$40.36$13.30M12,382,243
Matthew Gline
CEO, Director
Nov 12, 2026Tax withholding−1,600$41.85$66.96K16,391,229
Matthew Gline
CEO, Director
Nov 12, 2026Other−7,809$41.13$321.18K16,392,829
Matthew Gline
CEO, Director
Nov 12, 2026Other−41,179$40.36$1.66M16,400,638
Mayukh Sukhatme
President & CIO, Director
Nov 12, 2026Tax withholding−1,737$41.85$72.69K18,396,703
Mayukh Sukhatme
President & CIO, Director
Nov 12, 2026Other−8,482$41.13$348.86K18,398,440
Mayukh Sukhatme
President & CIO, Director
Nov 12, 2026Other−44,723$40.36$1.81M18,406,922
Frank Torti
President and Vant Chair
Nov 11, 2026Other−151,293$42.01$6.36M12,711,793
Frank Torti
President and Vant Chair
Nov 11, 2026Other−240,755$41.63$10.02M12,863,086
Matthew Gline
CEO, Director
Nov 11, 2026Other−18,905$42.01$794.20K16,441,817
Matthew Gline
CEO, Director
Nov 11, 2026Other−30,083$41.63$1.25M16,460,722
Mayukh Sukhatme
President & CIO, Director
Nov 11, 2026Other−20,533$42.01$862.59K18,451,645
Mayukh Sukhatme
President & CIO, Director
Nov 11, 2026Other−32,672$41.63$1.36M18,472,178
Richard Pulik
CFO
Nov 11, 2026Sale−47,635$41.89$2.00M222,046
Richard Pulik
CFO
Nov 11, 2026Sale−82,170$42.03$3.45M269,681
Richard Pulik
CFO
Nov 11, 2026Sale−45,195$41.47$1.87M351,851
Richard Pulik
CFO
Nov 11, 2026Option exercise+127,365$3.85$490.36K397,046
Eric Venker
President & Immunovant CEO
Nov 10, 2026Sale(10b5-1 plan)−29,749$41.00$1.22M811,211
Eric Venker
President & Immunovant CEO
Nov 10, 2026Sale(10b5-1 plan)−158,194$40.44$6.40M840,960
Frank Torti
President and Vant Chair
Nov 10, 2026Other−218,369$41.13$8.98M13,103,841
Frank Torti
President and Vant Chair
Nov 10, 2026Other−173,683$40.43$7.02M13,322,210
Matthew Gline
CEO, Director
Nov 10, 2026Other−32,490$41.13$1.34M16,490,805
Matthew Gline
CEO, Director
Nov 10, 2026Other−25,841$40.43$1.04M16,523,295
Mayukh Sukhatme
President & CIO, Director
Nov 10, 2026Other−32,882$41.13$1.35M18,504,850
Mayukh Sukhatme
President & CIO, Director
Nov 10, 2026Other−26,152$40.43$1.06M18,537,732
Richard Pulik
CFO
Nov 10, 2026Sale−125,000$41.20$5.15M269,681
Richard Pulik
CFO
Nov 10, 2026Option exercise+125,000$3.85$481.25K394,681
Eric Venker
President & Immunovant CEO
Nov 3, 2026Sale(10b5-1 plan)−200,000$36.31$7.26M999,154
Eric Venker
President & Immunovant CEO
Oct 28, 2026Sale(10b5-1 plan)−200,000$36.59$7.32M1,199,154
Epperly Melissa B,
Director
Oct 23, 2026Tax withholding−116$36.49$4.23K15,351
Epperly Melissa B,
Director
Oct 23, 2026Award+513––15,467
Ilan Oren
Director
Oct 23, 2026Award+810––124,490
James C. Momtazee
Director
Oct 23, 2026Tax withholding−77$36.49$2.81K112,265
James C. Momtazee
Director
Oct 23, 2026Award+383––112,342
Eric Venker
President & Immunovant CEO
Oct 20, 2026Sale(10b5-1 plan)−14,144$35.42$500.98K1,399,154
Eric Venker
President & Immunovant CEO
Oct 20, 2026Sale(10b5-1 plan)−185,856$35.09$6.52M1,413,298
Mayukh Sukhatme
President & CIO, Director
Oct 16, 2026Tax withholding−19,976$33.53$669.80K18,563,884
Matthew Gline
CEO, Director
Oct 16, 2026Tax withholding−34,638$33.53$1.16M16,549,136
Epperly Melissa B,
Director
Oct 1, 2026Sale(10b5-1 plan)−900$36.57$32.91K14,954
Epperly Melissa B,
Director
Oct 1, 2026Sale(10b5-1 plan)−16,850$36.08$607.95K15,854
Epperly Melissa B,
Director
Oct 1, 2026Option exercise+17,750$4.46$79.17K32,704
Mayukh Sukhatme
President & CIO, Director
Sep 30, 2026Tax withholding−46,879$36.57$1.71M18,583,860
Eric Venker
President & Immunovant CEO
Sep 30, 2026Sale(10b5-1 plan)−200,000$36.62$7.32M1,599,154
Eric Venker
President & Immunovant CEO
Sep 30, 2026Option exercise+200,000$3.85$770.00K1,799,154
Matthew Gline
CEO, Director
Sep 30, 2026Tax withholding−76,171$36.57$2.79M16,583,774
Frank Torti
President and Vant Chair
Sep 30, 2026Tax withholding+40,309$36.57$1.47M13,495,893
Jennifer Humes
Chief Accounting Officer
Sep 20, 2026Tax withholding−3,880$39.77$154.31K106,419
Richard Pulik
CFO
Sep 20, 2026Tax withholding−2,129$39.77$84.67K269,681
Meghan Fitzgerald
Director
Sep 16, 2026Award+5,054––41,162
Keith S. Manchester
Director
Sep 16, 2026Award+5,054––1,753,457
James C. Momtazee
Director
Sep 16, 2026Award+5,054––111,959
Daniel Allen Gold
Director
Sep 16, 2026Award+5,054––8,965,815
Ilan Oren
Director
Sep 16, 2026Award+5,054––123,680
Epperly Melissa B,
Director
Sep 16, 2026Award+5,054––14,954
Epperly Melissa B,
Director
Sep 15, 2026Sale(10b5-1 plan)−600$40.38$24.23K9,900
Epperly Melissa B,
Director
Sep 15, 2026Sale(10b5-1 plan)−4,338$39.65$172.00K10,500
Meghan Fitzgerald
Director
Sep 15, 2026Sale(10b5-1 plan)−4,712$39.68$186.97K36,508
Meghan Fitzgerald
Director
Sep 15, 2026Sale(10b5-1 plan)−400$40.45$16.18K36,108

Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.

Short interest

Shares sold short and not yet bought back, as of Oct 30, 2026 (FINRA, reported twice a month)

Short % of float
7.32%
46M shares short
Days to cover
6.1
At 8M shares a day
Change since last report
+12.9%
From 40M shares
Short volume, 20 days
57.6%
Of volume reported to FINRA

Shares sold short, last 12 months

Short sale volume counts trades marked short on any given day, including market-maker hedging, so it runs far higher than the share of Roivant Sciences's stock actually held short. Settlement fails (shares not delivered on time) peaked at 102,373 shares on Sep 9, 2026 over the last 90 days.

Planned insider sales

Notices of proposed sale filed on Form 144 before shares are sold

SellerFiledSharesMarket valuePlanned saleAcquired through
Mayukh Sukhatme
Officer, Director
Nov 10, 2026173,725$7.12MNov 10, 2026Performance Stock Units
Matthew Gline
Officer, Director
Nov 10, 2026164,136$6.73MNov 10, 2026Performance Stock Units
Frank Torti
Officer
Nov 10, 20261,234,964$50.73MNov 10, 2026Performance Stock Units
Richard Pulik
Officer, Director
Nov 10, 2026125,000$5.15MNov 10, 2026Exercise of Options Under a Registered Plan
Frank Torti
Officer
Nov 10, 20261,234,964$50.73MNov 10, 2026Performance Stock Units
Matthew Gline
Officer, Director
Nov 10, 2026164,136$6.73MNov 10, 2026Performance Stock Units
Mayukh Sukhatme
Officer, Director
Nov 10, 2026173,725$7.12MNov 10, 2026Performance Stock Units
Eric Venker
Officer
Nov 10, 2026187,943$7.62MNov 10, 2026Options Exercise - Grant Date 04/20/2022
Eric Venker
Officer
Nov 3, 2026200,000$7.26MNov 3, 2026Options Exercise - Grant Date 04/20/2022
Eric Venker
Officer
Oct 28, 2026200,000$7.32MOct 28, 2026Options Exercise - Grant Date 04/20/2022
Eric Venker
Officer
Oct 20, 2026200,000$7.02MOct 20, 2026RSU Grant 019326 - Grant Date 04/20/2022
Eric Venker
Officer
Sep 30, 2026200,000$7.32MSep 30, 2026Options Exercise - Grant Date 04/20/2022
Epperly Melissa B,
Director
Sep 15, 202622,688$930.66KSep 15, 2026Exercise of Stock Options
Meghan Fitzgerald
Officer
Sep 15, 20265,112$209.69KSep 15, 2026Restricted Stock Units
Meghan Fitzgerald
Director
Sep 8, 202620,000$698.60KSep 8, 2026Exercise of Stock Options

See a number that looks wrong?